Nautilus Biotechnology Inc Asset Resilience Ratio
Nautilus Biotechnology Inc asset resilience ratio. Nautilus Biotechnology Inc (NAUT) has an Asset Resilience Ratio of 43.32% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Nautilus Biotechnology Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nautilus Biotechnology Inc (2019–2025)
Asset resilience ratio of Nautilus Biotechnology Inc from 2019 to 2025. This chart shows how Nautilus Biotechnology Inc's Asset Resilience Ratio has changed over time. Read NAUT total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nautilus Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Nautilus Biotechnology Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $70.86 Million | 43.32% |
| Total Liquid Assets | $70.86 Million | 43.32% |
Asset Resilience Insights
- Very High Liquidity: Nautilus Biotechnology Inc maintains exceptional liquid asset reserves at 43.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nautilus Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Nautilus Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Nautilus Biotechnology Inc Asset Resilience Ratio by Year (2019–2025)
Nautilus Biotechnology Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Nautilus Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.63% | $91.02 Million | $191.11 Million | +5.50pp |
| 2024-12-31 | 42.12% | $102.25 Million | $242.74 Million | -8.28pp |
| 2023-12-31 | 50.41% | $154.02 Million | $305.56 Million | +30.42pp |
| 2022-12-31 | 19.98% | $69.95 Million | $350.05 Million | -20.20pp |
| 2021-12-31 | 40.18% | $160.11 Million | $398.45 Million | -7.03pp |
| 2020-12-31 | 47.21% | $40.13 Million | $85.01 Million | -39.42pp |
| 2019-12-31 | 86.64% | $16.06 Million | $18.54 Million | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument,… Read more